On November 16th, Dr. Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in the treatment of suicidal ideation and depression.
Javitt told Proactive in a video presentation that NRX is approaching the clinical trial enrollment goals for its partnered product NRX-101. In addition, NRX is opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression.
Read More – https://www.proactiveinvestors.com/companies/news/1033413/nrx-pharmaceuticals-founder-unveils-potential-treatment-for-suicidal-thoughts-and-depression-1033413.html
Also found in the following articles:
